Optomed Oyj (OPTOMED) Fair Value & Analysis
Healthcare · FI · Market cap €34.9M
Fair value as of: Jul 16, 2026
From 1 valuation models · updated 25 days ago
Share price +1.4% over the past month.
Below-average quality, and screening another 79% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (€0.4600). The favourable scenario is already priced in.
- Weak quality (30/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (€0.2400 to €0.4600) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.
How to read this chart
60‑month range €1.39 – €18.90 · fair‑value band €0.2400 – €0.4600 · the €1.75 price screens above the €0.3600 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 16, 2026.
Analysis
Optomed Oyj (OPTOMED) currently trades at €1.75, while our model-based Fair Value estimate is €0.3600, implying the stock looks roughly 79.5% overvalued today. The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Optomed Oyj generated revenue of €17.1M at a net margin of -38.8%. Revenue declined 5.6% year over year. It earns a return on equity of -27.9%. The balance sheet holds a net cash position of €6.4M. Fundamentals as of Jul 16, 2026
Our scenario range runs from €0.2400 (bear case) to €0.4600 (bull case); at €1.75, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 63% below its 52-week high and 32% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -53% fair-value upside, at -79%, OPTOMED screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when OPTOMED reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 16, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 32 · Market factors (momentum, volatility) 14
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Optomed Oyj, together with its subsidiaries, manufactures and sells handheld fundus cameras in Finland, rest of Europe, and internationally. The company operates in two segments, Devices and Software.
Full company description
Optomed Oyj, together with its subsidiaries, manufactures and sells handheld fundus cameras in Finland, rest of Europe, and internationally. The company operates in two segments, Devices and Software. It develops, manufactures, and sells fundus cameras for ophthalmologists, pediatricians, endocrinologists, neurologists, and primary health care professionals; and provides professional IT consulting services for government institutions. The company also provides camera products under the Optomed Smartscope Pro, Optomed Aurora, Optomed Aurora AEYE, Optomed Polaris, and Optomed Lumo brand names, as well as OEM cameras under the Volk Optical, Carl Zeiss Meditec, and Topcon brands. The company provides Avenue AI, an AI streamlines eye specialists' work and minimises screening costs; Avenue Eye Screen, a workflow management software for screening and monitoring of eye diseases; Avenue Flow, an eyecare management software; and Avenue Telemedicine, a remote analysis solution. In addition, it offers Cancer Screen, a screening process management software; Optomed Radiology Information System, a software solution for healthcare imaging units; Sectra PACS, a modular system for healthcare providers; Optomed Service Portal, a support function for healthcare units; Cephalometry, a powerful, flexible, and easy-to-use Windows software for orthodontics, oral and maxillofacial surgery; and Pathology PACS, which allows digital pathology images to be reviewed and shared. Optomed Oyj was incorporated in 2004 and is headquartered in Oulu, Finland.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Optomed Oyj reported revenue of €17.1M in FY2025 versus €14.9M in FY2021, a compound +3.6%/yr. Reported net income was −€6.6M in FY2025.
OPTOMED screens 79% overvalued. Compare with Veeva Systems Inc →
Peer Group
Health Information Services · 126 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Health Information Services median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $190.12 | $95.12 | -50% |
| Pro Medicus Limited PME | A$194.84 | A$23.74 | -88% |
| BrightSpring Health Services, Inc BTSG | $68.16 | $21.31 | -69% |
| HealthEquity, Inc HQY | $97.67 | $56.63 | -42% |
| Hinge Health, Inc HNGE | $88.80 | $24.03 | -73% |
| 10x Genomics, Inc TXG | $45.75 | $17.18 | -62% |
| Waystar Holding WAY | $22.69 | $12.86 | -43% |
| Doximity, Inc DOCS | $22.21 | $17.18 | -23% |
| Privia Health Group PRVA | $28.10 | $5.30 | -81% |
| Inventurus Knowledge Solutions Limited IKS | ₹1,846 | ₹860.28 | -53% |
Compare Optomed Oyj with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Optomed Oyj (OPTOMED) overvalued or undervalued?
What is the fair value of OPTOMED?
What is the quality score of OPTOMED?
What is the revenue of Optomed Oyj (OPTOMED)?
What is the net profit margin of OPTOMED?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Optomed Oyj and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.